Steve Scala
Stock Analyst at TD Cowen
(2.83)
# 1,897
Out of 5,048 analysts
31
Total ratings
73.08%
Success rate
13.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $211.96 | +6.15% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $46.02 | +28.21% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $81.72 | +16.25% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $82.49 | +63.66% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $24.66 | +29.76% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $896.53 | -44.23% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $123.86 | -15.23% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $37.30 | +47.45% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $211.96
Upside: +6.15%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $46.02
Upside: +28.21%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $81.72
Upside: +16.25%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $82.49
Upside: +63.66%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $24.66
Upside: +29.76%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $896.53
Upside: -44.23%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $123.86
Upside: -15.23%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $37.30
Upside: +47.45%